 ENT and allergy-focused company Optinose Inc NASDAQ: OPTN posted Q3 Xhance fluticasone propionate sales of 21.8 million, 41 YY, missing the consensus of 23.48 million. The Company held cash and cash equivalents of 84.2 million as of September 30, 2021. 